Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim After Bone Marrow Transplantation for Myelodysplastic Syndromes
NCT00003961Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 1999
- Primary completion
- Dec 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in myelodysplastic syndrome (MDS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Progression-Free Survival at 1 year. Started Apr 1999; status: completed.
02
Drugs
sargramostim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00003961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003961.